Mydecine seeks to become a psilocybin supplier for new applications for psilocybin-therapy under Canada’s SAP.

atai Life Sciences announces Investigational New Drug (IND) clearance from the FDA for PCN-101.

The Mental Health Crisis spirals. Psychedelic medicine advances. In 2022, “crisis” meets “opportunity”.

On January 5, 2022, Health Canada amendments to its Special Access Program has expanded access to psychedelic drug therapies. We explore the implications.

Field Trip announces receiving its USPTO patent for FT-104, including composition of matter.

Awakn announces strong results from its Phase II a/b clinical trial of a ketamine-assisted therapy for Alcohol Use Disorder (AUD).

Wesana announces a pre-IND meeting with the FDA for SANA-013 in March, it’s lead drug candidate for Traumatic Brain Injury.

On January 4, 2022, amendments to Health Canada’s Special Access Program took effect that explicitly include access to psychedelic medicine. We asked Numinus’ Payton Nyquvest to connect the dots on the impact of these new rules.

Mydecine announces the use of AI to accelerate identification of drug candidates for psychedelics research.

Magic mushrooms for your well-being? If you haven’t heard about psychedelics being used as a treatment for mental health disorders, this year may change that.